Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

vasogen

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

CalamineSimethiconeZinc Oxide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Anti-hsp60 and anti-hsp65 levels after VasoCare" Treatment
54) TREATMENT OF AUTOIMMUNE DISEASES 4,632,980 12/1986 Zee et al. ................................ 530/380 4,831,268 5/1989 Fisch… Expand
Is this relevant?
Review
2009
Review
2009
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
The increasing prevalence of heart failure poses enormous challenges for health care systems worldwide. Despite effective medical… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
BACKGROUND Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2008
2008
Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Administration of VP025 (Vasogen Inc.), a novel drug formulation based on phospholipid nanoparticles incorporating… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Role of Interleukin-4 in Regulation of Age-related Inflammatory Changes in the Hippocampus
Yvonne Nolan, Frank O. Maher||, Darren S. Martin, Rachael M. Clarke, Miriam T. Brady, Anthony E Bolton, Kingston H. G. Mills, and… Expand
Is this relevant?
2005
2005
Evidence of an Anti-Inflammatory Role for Vasogen’s Immune Modulation Therapy
We have reported that Vasogen’s immune modulation therapy (IMT), a procedure involving intramuscular administration of autologous… Expand
  • figure 1
Is this relevant?
2003
2003
Vasogen's immune modulation therapy (IMT) improves postischemic foot skin blood flow and transcutaneous pO(2) recovery rates in patients with advanced peripheral arterial occlusive disease.
AIM Vasogen's immune modulation therapy (IMT)* involves the ex vivo exposure of a sample of autologous blood to 3 oxidative… Expand
Is this relevant?
2002
2002
Attenuation of LPS-Induced Changes in Synaptic Activity in Rat Hippocampus by Vasogen’s Immune Modulation Therapy
Systemic injection of lipopolysaccharide (LPS) blocks the expression of long-term potentiation in the hippocampus of the rat… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2002
2002
A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with…
OBJECTIVES this study examined the effect of immune modulation therapy (IMT) on claudication distances. MATERIALS AND METHODS a… Expand
  • table 1
  • table 3
  • table 4
  • table 2
Is this relevant?
Review
2001
Review
2001
VasoCare. Vasogen.
Vasogen is developing VasoCare, an immune modulation therapy, as a potential treatment for peripheral vascular disease (PVD) and… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE